Dogwood Therapeutics, Inc. (DWTX) Form 8-K — Nov 5, 2026
Dogwood Therapeutics reported a Q3 2026 net loss of $4.9 million ($0.14 per share), sharply narrower than the $15.7 million ($8.20 per share) loss a year ago, driven largely by the absence of $12.0 million in IPR&D charges from the prior-year Serpin licensing deal.
Key figures
- Revenue
- 100000
- Total Assets
- 75608219
- Cash Position
- 4948266
- Runway
- through Q1 2027
- Phase2b patients
- 239
- Private placement
- 5000000
- Ga expense q3 2026
- 1576219
- Rd expense q3 2025
- 14521342
- Rd expense q3 2026
- 3352977
- Extension study patients
- 95
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.